11/5/2026

speaker
Conference Operator
Operator

Good day and thank you for standing by. Welcome to the Akiva's third quarter 2026 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising that your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your first speaker today, Mercedes Carrasco, Senior Director, IR. May begin.

speaker
Mercedes Carrasco
Senior Director, Investor Relations

Thank you, and welcome to Akebia's third quarter 2026 financial results and business updates conference call. Please note that a press release was issued earlier today, Thursday, November 5th, detailing our third quarter 2026 financial results. and that release is available on the investor section of our website. For your convenience, a replay of today's call will also be available on our website after we conclude. Joining me for today's call, we have John Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer. Dr. Steven Burke, our Chief Medical Officer and Nicholas Grund, Chief Commercial Officer are also available for questions. I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information describing these risks is included in the financial results press release that we issued on November 5th, as well as in the risks, factors, and management discussion and analysis section of our most recent annual and quarterly reports filed with the SEC. With that, I'd like to introduce our

speaker
John Butler
Chief Executive Officer

Thanks, Mercedes. Good morning, everyone, and thank you for joining us today. Late last month, Akibi joined our peers at ASN Kidney Week in Denver. I left the event with two important takeaways. First, I heard tremendous excitement about the voice trial data that Dr. Block of US Renal Care presented. We believe the data, which demonstrated a clear and compelling hospitalization outcomes benefit for Vatadustat versus an ESA, Those in a regimen that most dialysis providers have chosen to implement will have dialysis organizations thinking differently about Vafsio and over time has the potential to drive Vafsio to become standard of care. Second, the spotlight continues to shine on rare kidney disease therapeutic product development. And we're excited about the potential to show meaningful differentiation with our mid-stage pipeline assets across multiple rare kidney indications. We believe this would represent significant value for our shareholders. Now, with this backdrop, let me walk through Q3, starting with our commercial business. We're pleased with the pace at which we're adding patients from the midsize dialysis providers, including USRC, DCI, and IRC. Last quarter, the number of patients on Vafsio increased to about 11,500 patients on therapy, representing about 20% of patients treated for anemia within these three dialysis organizations. Also important, 25% of patients that had previously discontinued therapy have restarted. Even with this progress, I believe we have significant room to continue driving growth even within the mid-sized dialysis providers, but obviously and especially at the large dialysis organizations. Ovasio net product revenues were $14.8 million for the quarter. This is only a 3% increase versus the third quarter of last year, despite approximately 140% growth in the number of patients on therapy. There are a few somewhat related factors at play, but it was predominantly a drawdown of inventory based on a lower dose and dialysis compliance rate. If you recall, we told you that we're no longer getting data on average dose at providers who've moved to TIW dosing. When our largest customer looked at their utilization, they adjusted their purchases based on the average dose they were seeing versus what they expected. Our customer made their inventory assumptions expecting an average dose of 900 milligrams per dialysis treatment, but the average was about 810 milligrams. Even more impactful, patients have been less compliant with their dialysis sessions than expected. If a patient doesn't show up for dialysis, the patient doesn't receive a Vapcio dose if the unit is using observed dosing. These two factors combined meant that there was more inventory in their clinics at the end of last quarter, which impacted their purchases this quarter. So to make it very clear, when we use the updated dose and compliance data with the number of patients on therapy, end user demand was between $17 and $18 million for Q2 and between $19 and $20 million for Q3. Another takeaway from my conversations at ASN is that while dialysis providers have protocols in place As individual physicians start using Vapcio in greater numbers, they're using their own strategies to utilize the product and bring patients into or keep patients in the hemoglobin target range. It shouldn't be surprising. It took 20 years for physicians to figure out how to dose ESAs. It's gratifying to see prescribers recognize the benefits of Vapcio for their patients, though it would be easier for us if their approaches were a little more consistent. Our focus is to continue to drive more patients onto therapy and support physicians as they look for the best outcomes for their patients. Beyond the reduction in inventory based on dose and dialysis compliance, as we approach FAFSA's January 1st, 2027 Tdapa expiration, we expect a continued reduction in inventory levels. No provider wants drug on the shelf that have bought at a higher price when it no longer gets to bill for that price. Now, we're working proactively to manage this dynamic. To be clear, for Q4, we expect to see continued growth in patients on therapy. That's the most important metric for the long-term growth of the product. On January 1st, we begin our post-Tdapa launch. On that day, Vafsio access will expand beyond the Tdapa-only patients to nearly all clinically eligible patients. Treatment with Vafsio will be reimbursed as part of the dialysis bundle payment, and dialysis organizations will no longer be able to bill separately when they use the product. As we've always said, post-TDAPA will price Vafsio to remain competitive with ESA pricing to ensure providers can access an innovative treatment for patients even within the economic confines of a bundled payment system. So what does this mean for pricing in 2027 and beyond? Now while we're still working on some of our post-TDAPA contracts, We know ESA price has decreased over time, and now incorporating a somewhat lower dose and dialysis compliance, we expect the average annual cost of therapy to fall somewhere between $1,000 and $1,500. Certainly not the price you would normally expect for a product bringing the level of innovation that Vapcio brings, but these are the dynamics of the dialysis market. If we can make Vapcio's standard of care which means ultimately treating at least 200 to 250,000 patients. That would mean a potential multi-hundred million dollar peak revenue. So how are we gonna get there? As I said, in Q4, even though we expect our customers to be conservative with inventory, we expect to continue to see an increase in patients. We expect Q4 patient growth will be driven primarily by our current mid-sized dialysis providers, USRC, IRC, and DCI. We share our shareholders' desire to see DaVita and Fresenius begin contributing to our revenue. And while we have a post-TDAPA contract with DaVita for 2027, at their request, we're working on a multi-year extension of that contract. And they've outlined their plans to begin rolling out the product slowly, which we expect to start this quarter, and in a much more significant way early next year. It's clearly been frustrating for us that adoption among the large dialysis providers has not progressed more quickly. But in the end, it's clinical evidence that changes the way prescribers think about patient care. Let me give you a few highlights from the voice data presented by Dr. Block at ASN. The trial enrolled 2,116 patients and met the predefined stopping criteria with a win odds of 1.16 and a p-value of 0.0016. establishing non-inferiority and superiority of the primary composite endpoint due to reduction in hospitalizations. The data demonstrated that hospitalizations were 10% lower in patients treated with Vatadustat versus ESA without a significant difference in mortality rates. Exposure-adjusted serious adverse events were lower with Vatadustat with 1.21.5 events per 100 patient years compared to 134.2 events for 100 patient years for patients treated with ESAs. Given that SAEs generally drive hospitalization, this is not a surprising finding. As we've seen in the past, Vatadustat showed more stable hemoglobin control versus ESAs. In an exploratory endpoint, the data showed the odds of high hemoglobin excursions were reduced in patients treated with Vatadustat compared to ESA, while there was no overall difference in low excursions. There has never been an outcome study performed before voice that compared treatments for patients with anemia due to CKD that demonstrated an outcomes difference. And recall, like the voice primary endpoint, the post hoc wind statistics analysis of our Innovate study also demonstrated a statistically significant lower risk of dying or being hospitalized for patients receiving Vatadustat versus ESAs. The health economic analysis of the voice hospitalization benefit will be completed, but we presented an updated economic analysis from Innovate at the ASN. This analysis suggested that treatment with VASIO resulted in a $6,200 lower annual cost of hospitalization per patient compared with ESA. And based on the assumptions used in the analysis, if all eligible dialysis patients with anemia were treated with VASIO, It could result in more than 600,000 fewer hospital days versus CSA treatment. We have seen and know that adoption in nephrology, particularly dialysis, moves slowly. But this is the data that gives me the confidence to believe that VAPCO will ultimately become standard of care. This morning, we announced positive top-line results from the VOCAL study, which we conducted at the VITA clinics. One more study demonstrating Vatadustat dose-TIW is noninferior to ESA in maintaining hemoglobin. We look forward to continuing the analysis of VOCAL to see what further differentiation we may be able to uncover. Now, ASN was also a great meeting when considering our rare kidney disease pipeline. A significant part of the meeting agenda was dedicated to advances in treating rare kidney diseases. We presented preclinical data that informed our confidence in Prolisiglot for FSGS, as well as posters on our Phase II trial designs for both Ebrevifus and Prolisiglot. Additionally, Dr. Jim Tumlin presented to a full house in an exhibitor spotlight, focusing on both Proli and Ebre. I was pleased with the interest in both programs from the interactions the team had with investigators and potential investigators. As you know, both programs are enrolling their Phase II trials, probably in FSGS, in EBRI, and a basket trial in C3G, IGAN, and lupus nephritis, with initial data from the EBRI trial expected in 2027. We're excited about the opportunity for both products, but particularly with EBRI, our tissue-targeted next-generation complement inhibitor. While data will obviously help define our strategy and development priorities, We believe EBRI's differentiated approach will allow for strong positioning with the potential for similar efficacy, a potentially better safety profile, and potentially less frequent dosing regimen versus current products in diseases like C3G. We believe there's tremendous value in our pipeline that is underappreciated or ignored in Akebia's value today. Now let me turn it over to Erik to review our third quarter financial results.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API